Iazsmin Ventura
Rheumatology · Chicago, ILNPI 1225464290
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,140 of the $28,376 with a category attached, or 67.5%. Boehringer Ingelheim accounts for 75.4% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $17,993, more than ten times the $327 reported in 2019.
Across 80 payments — averaging $354.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$21K
- Octapharma USA, Inc.$5K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$354
- Takeda Pharmaceuticals U.S.A., Inc.$112
- Amgen$110
- plus $751 from 14 others
Across 5 payments — averaging $8905.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$44K
- Boehringer Ingelheim International GmbH$997
What the payments were for
- Consulting fees$19,14067%
- Speaking & faculty fees$4,50016%
- Travel & lodging$2,2988%
- Food & beverage$2,3538%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 26 | $21,389 |
| Octapharma USA, Inc. | 1 | $4,500 |
| Novartis | 4 | $1,160 |
| E.r. Squibb & Sons, L.L.C. | 9 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Amgen | 5 | $110 |
| AbbVie | 4 | $102 |
| Sobi, Inc | 2 | $92 |
| Genentech USA, Inc. | 5 | $89 |
| Pfizer | 4 | $88 |
| Johnson & Johnson | 1 | $85 |
| Sanofi | 2 | $63 |
| Inogen, Inc. | 3 | $54 |
| GSK | 3 | $46 |
| Argenx US, Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $25 |
| Insmed, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$4,500
- OFEV$122
- ORENCIA$120
How this compares
$28,376 in reported general payments places this provider in the 85th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 32 | $471,627 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 34 | $356,964 |
| Humira PenAdalimumab | 29 | $278,843 |
| BenlystaBelimumab | 25 | $120,554 |
| Actemra ActpenTocilizumab | 23 | $107,029 |
| Orencia ClickjectAbatacept | 11 | $62,969 |
| KevzaraSarilumab | 12 | $35,849 |
| RasuvoMethotrexate/Pf | 28 | $17,634 |
| Mycophenolate Mofetil | 63 | $15,587 |
| Mycophenolic AcidMycophenolate Sodium | 36 | $15,401 |
| MethotrexateMethotrexate Sodium | 101 | $3,497 |
| Hydroxychloroquine Sulfate | 57 | $1,852 |
| Leflunomide | 17 | $1,834 |
| Azathioprine | 30 | $1,679 |
| Tacrolimus | 11 | $1,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $46 | $120,55425 claims |
| SanofiKevzara | $63 | $35,84912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 287 rheumatology providers in Illinois.
Other rheumatology in Chicago
- Manish JainChicago$1.9M
- Theodore PincusChicago$524K
- Eric RudermanChicago$440K
- Anisha DuaChicago$280K
- Arthur MandelinChicago$270K
- Robert WoodrickChicago$143K
- Maria SosenkoChicago$87K
- Ailda NikaChicago$74K
- Duncan MooreChicago$71K
- Timothy NiewoldChicago$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.